Descripción de negocio
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets five hematology/oncology drugs, and expects an FDA decision on another hematology drug later this year. Additionally, Spectrum's pipeline includes three drugs targeting blockbuster markets in advanced stages of clinical development. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies.
Consejo de gestión & Consejo de supervisión
| CEO |
| Joseph Turgeon |
| Consejo de gestión |
| Kurt Gustafson, Francois Lebel, Keith M. McGahan, Thomas J. Riga |
| Consejo de supervisión |
| William L. Ashton, Bernice R. Welles, Dolatrai M. Vyas, Jeffrey L. Vacirca, Joseph W. Turgeon, Nora Brennan, Seth H.Z. Fischer |
Datos de la empresa
| Nombre: |
Spectrum Pharmaceuticals Inc. |
| Dirección: |
11500 S. Eastern Avenue, Suite 240,Henderson, NV 89052, USA |
| Teléfono: |
+1-702-935-6300 |
| Fax: |
+1-702-260-7405 |
| E-mail: |
-
|
| Internet: |
https://www.sppirx.com/ |
| Industria: |
Biotechnology |
| Sector: |
Biotechnology |
| Subsector: |
Biotechnology |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
61.22% |
| Fecha de OPI: |
- |
Relación con inversores
| Nombre: |
Shiv Kapoor |
| IR teléfono: |
- |
| IR-fax: |
- |
| IR e-mail: |
IR@sppirx.com
|
